Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotect in pregnant women with primary HCMV infection
NCT00881517Phase 3Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jun 2009
- Primary completion
- Oct 2011
- Modality
- IgG Antibodies, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus infection (CMV) comparing Cytotect with Placebo (2 arms). Primary endpoint: Evidence of congenital HCMV infection in the fetus/newborn. Started Jun 2009; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00881517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881517.